Under construction – not a live service
Sign in
Taking people in GermanyNo phase

Studies how new epilepsy criteria affect diagnosis after a first seizure

Follows adults after a first seizure to see how new epilepsy diagnostic criteria apply.

Plain-language title generated from the registry record
Registry title: Effect of the New Definition of Epilepsies of the ILAE of 2014 on the Diagnosis After the First Seizure

Key facts

Where
Marburg, GermanySee the site

Where in Germany

  • c/o Klinik für NeurologieMarburg, GermanyTaking people

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?
Print a page for my doctor

Trial details

Who runs it
University Hospital Marburg
Trial code
NCT06836687
Record updated
20 February 2025
Original description
The present study is a prospective study on the development of seizure frequency, medication adherence, quality of life and cognitive performance after a first epileptic seizure using the new diagnostic criteria for epilepsy of the International League Against Epilepsy of 2014 at the time of diagnosis.Read full original descriptionShow less

Monocentric Study to Investigate the Effect of the New Definition of Epilepsies of the International League Against Epilepsy of 2014 on the Diagnosis After the First Seizure, on Patient Satisfaction, Cognition and Health Economic Factors

The present study is a prospective study on the development of seizure frequency, medication adherence, quality of life and cognitive performance after a first epileptic seizure using the new diagnostic criteria for epilepsy of the International League Against Epilepsy of 2014 at the time of diagnosis.

Inclusion: Completion of the 18th year of life; first epileptic seizure; Ability to understand the patient information and to give written consent; Written consent for voluntary participation in the study.

Exclusion: Chronic drug or alcohol abuse in the last two years.

ClinicalTrials.gov NCT06836687